Background The gold standard endpoint in randomised trials of locally advanced head and
neck squamous-cell carcinoma (HNSCC) is overall survival. Our objective was to study …

Background There are still many unresolved questions in the management of locally
advanced Head and Neck Cancer (HNC). Many chemotherapeutic drugs and radiotherapy …

Background Randomised, controlled trials and meta-analyses have shown the survival
benefit of concomitant chemoradiotherapy or hyperfractionated radiotherapy in the treatment …

Background Despite more than 70 randomised trials, the effect of chemotherapy on non-
metastatic head and neck squamous-cell carcinoma remains uncertain. We did three meta …

Background Between 1990 and 2000, we examined the effect of timing of non-platinum
chemotherapy when combined with radiotherapy. We aimed to determine whether giving …

Background Despite multimodal therapy, 5-year overall survival for locally advanced head
and neck squamous cell carcinoma (HNSCC) is about 50%. We assessed the addition of …

During the past 20 years, treatments for head and neck squamous cell carcinoma (HNSCC)
have changed dramatically owing largely to the advent of novel approaches such as …

Background The relative efficacy of the addition of induction chemotherapy to
chemoradiotherapy compared with chemoradiotherapy alone for patients with head and …

Purpose Chemoradiation with cisplatin 100 mg/m2 given once every 3 weeks is the
standard of care in locally advanced head and neck squamous cell cancer (LAHNSCC) …

This review will discuss the evolution of the role of chemotherapy in the treatment of locally
advanced head and neck cancer (HNC), over the last few decades. Studies were identified …